Apyx Medical Corporation (NASDAQ:APYX) Given Average Rating of “Moderate Buy” by Brokerages

Apyx Medical Corporation (NASDAQ:APYX) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $6.60.

Several research analysts have recently issued reports on APYX shares. Zacks Research raised Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. HC Wainwright started coverage on shares of Apyx Medical in a research note on Monday, July 13th. They issued a “buy” rating and a $7.00 price objective on the stock. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th.

Apyx Medical Price Performance

Shares of NASDAQ:APYX opened at $4.07 on Tuesday. The firm has a market capitalization of $170.57 million, a price-to-earnings ratio of -18.50 and a beta of 1.37. The company has a debt-to-equity ratio of 2.68, a current ratio of 5.80 and a quick ratio of 4.79. The business’s 50 day simple moving average is $4.25 and its 200-day simple moving average is $3.91. Apyx Medical has a 12 month low of $1.59 and a 12 month high of $5.08.

Apyx Medical (NASDAQ:APYX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.06. The firm had revenue of $12.49 million during the quarter, compared to the consensus estimate of $10.53 million. Apyx Medical had a negative return on equity of 88.47% and a negative net margin of 16.40%. As a group, equities analysts forecast that Apyx Medical will post -0.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Perkins Capital Management Inc. grew its holdings in shares of Apyx Medical by 4.9% during the fourth quarter. Perkins Capital Management Inc. now owns 85,000 shares of the company’s stock worth $298,000 after buying an additional 4,000 shares in the last quarter. State Street Corp lifted its stake in shares of Apyx Medical by 6.8% during the fourth quarter. State Street Corp now owns 116,706 shares of the company’s stock valued at $408,000 after buying an additional 7,400 shares during the period. Geode Capital Management LLC lifted its stake in shares of Apyx Medical by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 358,829 shares of the company’s stock valued at $1,257,000 after buying an additional 7,551 shares during the period. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Apyx Medical by 0.8% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock valued at $3,842,000 after buying an additional 8,067 shares during the period. Finally, Nwam LLC acquired a new stake in Apyx Medical during the first quarter worth approximately $47,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.